{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-235.3","upperLimit":"110.1","value":"19.93"},{"groupId":"OG001","lowerLimit":"-77.7","upperLimit":"93.1","value":"12.84"},{"groupId":"OG002","lowerLimit":"-156.4","upperLimit":"56.4","value":"11.34"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"36"}],"units":"Participants"}],"description":"Change in stair climb power from baseline to 4 months. Stair climb power is defined power (watts)=\\[9.8 m/sec\\*\\*2\\]\\*\\[weight (kg)\\]\\*\\[height of 12 steps(meters)\\]/ \\[time (seconds) up the 12 steps\\].","dispersionType":"Full Range","groups":[{"description":"1 mg","id":"OG000","title":"GTx -024"},{"description":"3 mg","id":"OG001","title":"GTx-024"},{"description":"Placebo","id":"OG002","title":"3 mg of Placebo"}],"paramType":"MEDIAN","populationDescription":"The subjects were in the MITT population (had a post baseline DEXA) and had a month 4 stair climb assessment (observed cases).","reportingStatus":"POSTED","timeFrame":"Four Months","title":"To Assess the Efficacy of GTx-024 on Muscle Function (Performance) as Measured by Stair Climb.","type":"SECONDARY","unitOfMeasure":"watts"}